Syntilio, the health technology startup founded by former FocusCura executives, has successfully closed a new investment round with healthcare investor NextGen Ventures 2 and a group of informal investors. This investment will help accelerate the development of the company's groundbreaking software platform that aims to streamline remote and cross segment healthcare delivery.
Syntilio's software platform enables healthcare providers to service remote patients and manage their care more efficiently. The platform utilises cutting-edge technology to gather patient data and provide AI supported, real-time insights, allowing healthcare providers (“triagist”) to make more informed decisions, organise the right form of follow-up and provide better care.
NextGen Ventures 2 is a perfect match as NextGen’s second fund is themed “Data is Next”. It aims to invest its capital in innovative, data driven companies, thus contributing to better, more efficient and affordable healthcare. The group of informal investors include industry leaders and technology investors, who recognise the significant potential of Syntilio's innovative solution.
"We are thrilled to announce the successful closing of this investment round," said Rimon Hanna and Raoul Zaal of Syntilio. "This funding will help us to support even more healthcare organisation with our revolutionary software platform and accelerate our mission to bring healthcare professionals and patients closer together. With our platform warm, personal care is possible, even when patients are serviced remotely."
"We believe Syntilio as a company has the potential to improve remote patient care,” said Matthijs Blokhuis, Director at NextGen Ventures. “We are excited to partner with Syntilio and support their mission to streamline healthcare delivery and improve patient outcomes and value."
The investment will also support the expansion of Syntilio's team and the development of new features and capabilities for the software platform. With the support of the investment, Syntilio is well-positioned to become a leader in the rapidly growing remote patient care market.
Syntilio is a health technology company, founded by Rimon Hanna and recently joined by former FocusCura CEO Raoul Zaal. Both entrepreneurs bring years of experience in health and technology. Syntilio is based in the Netherlands, and focuses on optimising remote and cross segment patient care. The company's software platform enables healthcare providers to remotely monitor patients and manage their care more efficiently. Syntilio's mission is to improve both efficiency and patient outcomes by streamlining healthcare delivery through smart, data driven technology.
About NextGen Ventures 2
NextGen Ventures 2 is an investment fund investing in knowledge-intensive companies that enable transformation in health care. We actively work with our portfolio companies to develop and market potential breakthrough innovations in health care IT and medical technology that provide meaningful results for people, patients, and professionals. For more information, please visit www.nextgenventures.nl.